About US
Contact us
-
Eisai's oncology unit cut; WuXi, Samsung expansions; BeiGene, Novartis' PD-1 pivotEisai is shutting down an oncology venture for good. Continuing the recent CDMO expansion spree,Wuxi Biologics is plotting a $1.4 billion R&D and manufacturingsite in Singapore, just as Samsung B2022/8/24
-
Pisgah Labs to spend $55M to upgrade North Carolina facilityPisgah Laboratories, an API maker, will invest$55 millionto upgrade its manufacturing facility in Pisgah Forest, North Carolina, to include sterile injectables and liquid filling operations.2022/8/22
-
Takeda's cancer drug woes; Merck's 2nd Kelun ADC deal; Astellas' cell and gene therapy hubTakeda's oncology department has been hit hard thanks to U.S. generic entry to Velcadeand other problems. Merck signs a near-$1 billion deal with Kelun Biotech for the Chinese biotech's antibody-drug2022/8/22
-
AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cutsIn another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers.2022/8/18
-
Pfizer partner CStone explores sale as US path blocked, Chinese competition heats up: BloombergA Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceut2022/8/18
-
AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cutsIn another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers.2022/8/16
-
Pfizer partner CStone explores sale as US path blocked, Chinese competition heats up: BloombergA Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceut2022/8/16
-
WuXi unveils new production capabilities at Changzhou campus amid expansion pushWuXi STA, a part of WuXi AppTec,unveilednew large-scale oligonucleotide and peptide manufacturing capabilities at its Changzhou production campus. The 30,570-square-foot oligonucleotide f2022/8/11
-
BeiGene R&D chief's I-O ambitions; Legend scraps CAR-T programBeiGene's R&D chief talked to Fierce Biotech about the company's PD-1 plans and how its TIGITplans are still alive despite Roche's recent trial failures. Expanding on novel technologies, BeiGenea2022/8/11
-
Athenex unloads stake in Chinese API production business for $19M to bolster its financialsStruggling biotech Athenexunloadedall of its equity interests in its Chinese subsidiaries that produce APIs as part of a $19 million deal with TiHe Capital of Beijing. Under terms of the2022/8/9